The first step in infection of human T cells with human immunodeficiency virus (HIV) is binding of viral envelope glycoprotein gpl20 to its cellular receptor, CD4. The specificity of this interaction has led to the development of soluble recombinant CD4 (rCD4) as a potential antiviral and therapeutic agent. We have previously shown that crude preparations of rCD4 can indeed block infection of T cells by HIV type 1 (HIV-1). Here we present a more detailed analysis of this antiviral activity, using HIV-1 infection of the T lymphoblastoid cell line H9 as a model. Purified preparations of rCD4 blocked infection in this system at nanomolar concentrations; combined with the known affinity of the CD4-gpl20 interaction, this finding suggests that the inhibition is simply due to competition for gpl20 binding. As predicted, rCD4 had comparable activity against all strains of HIV-1 tested and significant activity against HIV-2. Higher concentrations of rCD4 blocked infection even after the virus had been adsorbed to the cells. These findings imply that the processes of viral adsorption and penetration require different numbers of gpl20-CD4 interactions. Recombinant CD4 was able to prevent the spread of HIV infection in mixtures of uninfected and previously infected cells. Our studies support the notion that rCD4 is a potent antiviral agent, effective against a broad range of HIV-1 isolates, and demonstrate the value of purified rCD4 as an experimental tool for studying the mechanism of virus entry into cells.
Infection by human immunodeficiency virus (HIV), the causative agent of acquired immunodeficiency syndrome (2, 11, 21) , is largely defined by its cellular receptor, CD4. A role for membrane glycoprotein CD4 in the process of infection was first proposed on the basis of a correlation between expression of CD4 on certain lymphocytes and their susceptibility to infection (17, 26) . Direct involvement of this surface protein in infection is now established by the finding that anti-CD4 antibodies block infection by HIV (1, 8, 24, 30) and transfer of CD4 to previously CD4-negative cells confers infectability (3, 23) . Furthermore, HIV envelope glycoprotein gpl20 binds to CD4 with high affinity and forms stable complexes (20, 22, 25, 32) .
Although gpl20 shows extensive genetic variation between HIV strains, potentially complicating the development of effective vaccines, all strains appear to bind to monomorphic receptor CD4. This implies that at least one region of gpl20 retains a conserved function and thus represents an attractive, stable target for an antiviral agent. While structural studies, such as those defining the subregions of gpl20 and CD4 involved in their interaction (3, 4, 18-20, 27, 29) , may eventually facilitate development of useful synthetic blocking agents (16) , the most direct approach is to exploit the known gpl20-binding properties of CD4. Therefore, we (32) and others (6, 9, 10, 15, 34,) have expressed soluble forms of recombinant CD4 (rCD4), have shown that rCD4 retains gpl20-binding activity, and have demonstrated that soluble rCD4 can block infection by HIV in vitro.
In this investigation, we examined the ability of purified * Corresponding author.
soluble rCD4 to block genetically diverse isolates of HIV and examined the effects of rCD4 on viral adsorption and penetration by using temperature to dissect these stages of viral infection. Our results show that rCD4 is effective against a diverse range of HIV isolates and reveal that different concentrations of rCD4 are required to inhibit the different stages of viral entry, providing insight into the mechanisms by which rCD4 acts to block each stage of infection.
MATERIALS AND METHODS Cells and virus. All experiments were performed with the H9 cell line originally obtained from Robert Gallo (National Cancer Institute, Bethesda, Md.). HIV type 1 (HIV-1) strain IIIB (11), also obtained from R. Gallo, was propagated by the method of Vujcic et al. (35) . HIV-1 strain 906 was isolated in our laboratory from a male European patient with HIV-related dementia whose only known risk factor was sexual contact with a woman from Chad. HIV-1 strain AL, isolated from a Haitian patient in Boston, Mass., was provided by David Ho while at Massachusetts General Hospital, Boston (14) . HIV-1 strain RJ4029 was isolated in our laboratory from a Haitian male with Kaposi's sarcoma.
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The nondenatured, glycosylated protein was purified to greater than 99% purity.
RT assay. The assay for HIV reverse transcriptase (RT) was performed as previously described (12, 28) . Virus was concentrated from 1 ml of tissue culture supernatants by incubation with 0.5 ml of polyethylene glycol-0.4 M NaCl overnight at 4°C. Control experiments indicated that rCD4 did not affect the RT assay.
Infection conditions. Infection of H9 cells was performed as described previously (12) 105 cpm/ml) were infected cultures to which no rCD4 was added.
Each bar represents the mean of two cultures.
(each stock adjusted to 100 TCID50 per culture). Soluble rCD4 had no effect on H9 cell viability, growth, or morphology in this culture system. Pretreatment with rCD4. When higher concentrations of rCD4 were present during incubation of virus with cells at 4°C, infection was also blocked (Fig. 1) Postpenetration inhibition. When rCD4 was added to previously infected H9 cell cultures (100 TCID50 of HIV-1), significant inhibition was observed, as measured by reduction in RT activity at the end of the 7-day culture period (Fig.  2) . The greatest inhibition (>80%) was observed when rCD4 was added within the first 2 days of infection and maintained throughout the culture period. Conversely, when rCD4 was present only during the first or last 2 days of the 7-day culture period, little inhibition (<50%) was observed.
Inhibition of cell-to-cell transfer of HIV. HIV spread rapidly from chronically infected cells to uninfected cells in cultures containing control medium or low concentrations, 0.01 or 0.1 ,ug/ml, of CD4 (Fig. 3) . Cultures containing 1.0 or 10 ,ug of rCD4 per ml showed no evidence of spread of infection during the initial 14-day period. At this time, however, infected cells were still present in the 1.0-and 10-pLg/ml rCD4 cultures, because removal of rCD4 allowed rapid spread of infection with kinetics similar to the that of the initial control medium culture.
Inhibition of HIV-1 and HIV-2 strains. Earlier reports (9, 10, 15, 32, 34) of HIV-1 inhibition by rCD4 focused on a single HIV-1 strain, IIIB. To confirm the inhibitory effect of rCD4 against multiple isolates of HIV (6), we performed the following experiment. The titers of three additional HIV-1 strains, all confirmed to be significantly different by restriction endonuclease mapping and partial nucleic acid sequence determination (data not shown), were determined in our 7-day H9 cell system, and 100-TCID50 challenge inocula were prepared. With the continuous-inhibition format, rCD4 inhibition curves were obtained for the different strains (Fig.  4) . A similar experiment was performed with HIV-2 strain LAV-2ROD (7) . Each curve presented in Fig. 4 is the mean of at least two experiments. While some HIV-1 strains showed reproducible differences in sensitivity to inhibition, the shapes of the titration curves were similar for all four HIV-1 isolates tested. In contrast, HIV-2 showed both an inhibition curve shape and a sensitivity to low rCD4 concentrations that appeared to be different from those of HIV-1. probability that the high density of interactions required for were infected with 100 TCID50 of each viral strain in the virus penetration can occur. If gp120-CD4 interactions are of different concentrations of rCD4 (continuous-inhibition also necessary to the progression of fusion, rCD4 could ns; see Materials and Methods). Infection was monitored by block this progression even after fusion has been initiated. ng supernatant RT activity after 7 days in culture. The Even after the initial infection by virions is completed, or HIV-1 IIIB are those presented in Fig. 1. HIV-1 The primary difference between cell-to-cell spread of iave shown that rCD4 inhibited infection by free infection and free-virion infection may be that infected cells in vitro at a concentration of 0.3 p.g/ml (7 nM) when produce virus near the target with respect to both space and or and virus were added together (Fig. 1) . Indeed, time, so the inoculum is essentially fresh and concentrated.
ie virus was preincubated with rCD4 and rCD4 was In our cell-mixing system (Fig. 3) rCD4 (9, 10, 15, 32, 34) . The results presented here confirm r, we consider it more likely that inhibition of viral that rCD4, as recently reported (6) , is not a type-specific ion is the major, and possibly the only, mechanism inhibitor, since it can block infection by HIV-1 strains quite ch rCD4 inhibits infection by free virus. rCD4 has different from IIIB (for example, HIV-1 AL has 83.5% amino sly been shown to block adsorption of virus to cells acid identity to HIV-1 IIIB; D. Dowbenko, personal comaddition, the finding that HIV-1 virions shed their munication) and by HIV-2 (39.4% amino acid identity to eadily (31) suggests that CD4 inactivates HIV simply HIV-1 IIIB) (13) . The inhibition curves for the various iestering virion-bound gpl20 until it is lost from the HIV-1 strains had similar slopes, suggesting that the affinendering the virion uninfectious. If this process does ities of the various gp120 molecules for rCD4 are comparathe results of our pretreatment experiments (Fig. 1) ble. Because the sizes of the viral inocula used in these e interpreted to indicate that dissociation of rCD4 experiments were determined by using the infectious titer of irus is slow relative to the time for which the virus the virus rather than the total amount of gpl20 or the total i infectious. with the antigenic character of the strain being tested. These differences in infectivity-to-viral protein ratios, rather than affinity differences, are the most likely explanation for the observed differences in sensitivity to rCD4 inhibition among the HIV-1 strains tested. The rCD4 inhibition curve for HIV-2 strain LAV-2 is clearly different from those of the HIV-1 strains, requiring higher rCD4 concentrations for full inhibition and displaying a shallower slope. The reason for this difference is not clear, but a difference would be expected if HIV-2 gpl20 had a lower affinity for CD4 (whether recombinant or cell surface) or if HIV-2 virions had a higher density of gpl20 on their surface.
Our results may have relevance to the therapeutic application of soluble rCD4, since the concentrations of H9 cells in these in vitro experiments are comparable to those of CD4+ cells in the bloodstream. The levels of rCD4 required in our assays to block HIV-1 infection completely are probably achievable in the blood of infected patients, as suggested by half-life studies with animal models (5). Furthermore, our results strongly support the idea that rCD4 will be effective in blocking infection by most or all strains of HIV and in blocking the spread of infection both by free virions and by cell-to-cell contact.
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